• The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease 

      Brakedal, Brage; Dölle, Christian; Riemer, Frank; Ma, Yilong; Nido, Gonzalo Sanchez; Skeie, Geir Olve; Craven, Alexander R.; Schwarzlmüller, Thomas; Brekke, Njål; Diab, Joseph; Sverkeli, Lars Jansen; Skjeie, Vivian; Varhaug, Kristin Nielsen; Tysnes, Ole-Bjørn; Peng, Shichun; Haugarvoll, Kristoffer; Ziegler, Mathias; Grüner, Renate; Eidelberg, David; Tzoulis, Charalampos (Journal article; Peer reviewed, 2022)
      We conducted a double-blinded phase I clinical trial to establish whether nicotinamide adenine dinucleotide (NAD) replenishment therapy, via oral intake of nicotinamide riboside (NR), is safe, augments cerebral NAD levels, ...
    • A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population 

      Brakedal, Brage; Toker, Lilah; Haugarvoll, Kristoffer; Tzoulis, Charalampos (Journal article; Peer reviewed, 2022)
      Epidemiological studies of Parkinson’s disease (PD) show variable and partially conflicting findings with regard to incidence, prevalence, and mortality. These differences are commonly attributed to technical and methodological ...
    • NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study 

      Brakedal, Brage; Tzoulis, Charalampos; Tysnes, Ole-Bjørn; Haugarvoll, Kristoffer (Journal article; Peer reviewed, 2021-09-07)
      Objective: Whether use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of incident Parkinson’s disease (PD) remains unresolved. Here, we employed the Norwegian Prescription Database to examine whether NSAID ...